[Federal Register Volume 79, Number 81 (Monday, April 28, 2014)]
[Notices]
[Page 23373]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2014-09561]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Importer of Controlled Substances; Notice of Application; 
Research Triangle Institute

    Pursuant to 21 CFR 1301.34(a), this is notice that on February 12, 
2014, Research Triangle Institute, Poonam G. Pande, Ph.D. RPH, RAC, 
Hermann Building, East Institute Drive, P.O. Box 12194, Research 
Triangle Park, North Carolina 27709, made application by written 
correspondence to the Drug Enforcement Administration (DEA) for 
registration as an importer of Noroxymorphone (9668) a basic class of 
controlled substance listed in schedule II.
    The company plans to import small quantities of the listed 
controlled substances for the National Institute on Drug Abuse (NIDA) 
for research activities.
    Any bulk manufacturer who is presently, or is applying to be, 
registered with the DEA to manufacture such basic class of controlled 
substance listed in schedule I or II, which fall under the authority of 
section 1002(a)(2)(B) of the Act (21 U.S.C. 952(a)(2)(B)) may, in the 
circumstances set forth in 21 U.S.C. 958(i), file comments or 
objections to the issuance of the proposed registration and may, at the 
same time, file a written request for a hearing on such application 
pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 
1316.47.
    Any such written comments or objections should be addressed, in 
quintuplicate, to the Drug Enforcement Administration, Office of 
Diversion Control, Federal Register Representative (ODW), 8701 
Morrissette Drive, Springfield, Virginia 22152; and must be filed no 
later than May 28, 2014.
    This procedure is to be conducted simultaneously with, and 
independent of, the procedures described in 21 CFR 1301.34(b), (c), 
(d), (e), and (f). As noted in a previous notice published in the 
Federal Register on September 23, 1975, 40 FR 43745-46, all applicants 
for registration to import a basic class of any controlled substance in 
schedule I or II are, and will continue to be, required to demonstrate 
to the Deputy Assistant Administrator, Office of Diversion Control, 
Drug Enforcement Administration, that the requirements for such 
registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 
1301.34(b), (c), (d), (e), and (f) are satisfied.

    Dated: April 21, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2014-09561 Filed 4-25-14; 8:45 am]
BILLING CODE 4410-09-P